Get the Stockscreener App
7.70
3.51%
-0.28
Cns Pharmaceuticals Inc stock is traded at $7.70, with a volume of 15,894.
It is down -3.51% in the last 24 hours and down -24.61% over the past month.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.
See More
Previous Close:
$7.98
Open:
$8.01
24h Volume:
15,894
Relative Volume:
0.12
Market Cap:
$4.23M
Revenue:
-
Net Income/Loss:
$-17.06M
P/E Ratio:
-0.1089
EPS:
-70.7173
Net Cash Flow:
$-14.18M
1W Performance:
-12.70%
1M Performance:
-24.61%
6M Performance:
-86.51%
1Y Performance:
-95.59%
1-Day Range:
$7.70
$8.2373
1-Week Range:
$7.50
$9.0794
52-Week Range:
$7.50
$221.94
Cns Pharmaceuticals Inc Stock (CNSP) Company Profile
Name
Cns Pharmaceuticals Inc
Sector
Industry
Phone
1-800-946-9185
Address
2100 WEST LOOP SOUTH, HOUSTON
Compare CNSP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CNSP
Cns Pharmaceuticals Inc
|
7.70 | 4.23M | 0 | -17.06M | -14.18M | -70.72 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Cns Pharmaceuticals Inc Stock (CNSP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-28-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Aug-24-20 | Initiated | Ladenburg Thalmann | Buy |
Cns Pharmaceuticals Inc Stock (CNSP) Latest News
Should I hold or sell CNS Pharmaceuticals Inc. stock in 2025Pre Market Forecasts That Work - jammulinksnews.com
What is the dividend policy of CNS Pharmaceuticals Inc. stockFinancial News Outlook For 2025 - jammulinksnews.com
Is CNS Pharmaceuticals Inc. stock overvalued or undervaluedMarket Forecast Signals For Fast Growth - jammulinksnews.com
CNS Pharmaceuticals Inc. Company’s Quarterly Earnings Growth: What the Numbers SaySwing Setup With Technical Confirmation Explained - metal.it
How does CNS Pharmaceuticals Inc. compare to its industry peersBeginner Investor Watchlist For 2025 - jammulinksnews.com
What makes CNS Pharmaceuticals Inc. stock price move sharplyTrade Insight With Community Collaboration Supported - metal.it
Published on: 2025-07-28 14:09:47 - metal.it
Will CNS Pharmaceuticals Inc. outperform the market Free Buy Low Sell High Stock Watch - Newser
Is it the right time to buy CNS Pharmaceuticals Inc. stockHigh-yield investments - jammulinksnews.com
What makes CNS Pharmaceuticals Inc. stock price move sharply 2-Day Signal Watch with Forecast Outcome - metal.it
Why is CNS Pharmaceuticals Inc. stock attracting strong analyst attentionCapitalize on trading strategies that deliver - jammulinksnews.com
How strong is CNS Pharmaceuticals Inc. company’s balance sheetExplosive earnings growth - jammulinksnews.com
Does CNS Pharmaceuticals Inc. stock perform well during market downturnsUnprecedented market success - jammulinksnews.com
Published on: 2025-07-27 20:34:14 - jammulinksnews.com
CNS Pharmaceuticals Inc. Stock Analysis and ForecastFree Market Dynamics Reports - PrintWeekIndia
What drives CNS Pharmaceuticals Inc. stock priceFree Stock Movement Tracking - Autocar Professional
What analysts say about CNS Pharmaceuticals Inc. stockFree Consultation - Autocar Professional
Is CNS Pharmaceuticals Inc. a good long term investmentSkyrocketing returns - jammulinksnews.com
Why CNS Pharmaceuticals Inc. stock attracts strong analyst attentionPrecision Entry Strategy - beatles.ru
CNS Pharmaceuticals Announces Reverse Stock Split - TipRanks
CNS Pharmaceuticals to Participate in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference - 富途牛牛
CNS Pharmaceuticals (NASDAQ: CNSP) CEO Featured In Virtual Investor Summer Spotlight Conference - Barchart.com
CNS Pharmaceuticals CEO Shares Brain Cancer Treatment Vision at Investor Conference | CNSP Stock News - Stock Titan
CNS Pharmaceuticals CEO Shares Vision at Virtual Investor Conference - citybuzz -
CNS Pharmaceuticals To Carry Out 1-for-12 Reverse Stock Split On July 22nd, 2025 - 富途牛牛
CNS Pharmaceuticals Implements 1-for-12 Reverse Stock Split to Consolidate Shares and Improve Market Position - AInvest
Published on: 2025-07-19 01:04:34 - jammulinksnews.com
CNS Pharmaceuticals (NASDAQ: CNSP) Announces 1-for-12 Reverse Stock Split Effective July 22 - Barchart.com
CNS Pharmaceuticals announces 1-for-12 reverse stock split By Investing.com - Investing.com Nigeria
Cns Pharmaceuticals Inc Stock (CNSP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):